Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.45 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.45 |
| ▸ | HTR3B | O95264 | 2/20 | 0.45 |
| ▸ | HTR3A | P46098 | 2/20 | 0.45 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.45 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.45 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9613561 | 1.00 | CHRM2 (0.47) | CHRM2CHRM4CHRM1CHRM3MAPT | |
| SCHEMBL2003265 | 1.00 | CHRM2 (0.47) | CHRM2CHRM4CHRM1CHRM3MAPT | |
| SCHEMBL4563291 | 1.00 | CHRM2 (0.47) | CHRM2CHRM4CHRM1CHRM3MAPT | |
| SCHEMBL2003263 | 1.00 | CHRM2 (0.47) | CHRM2CHRM4CHRM1CHRM3MAPT | |
| SCHEMBL11982157 | 0.89 | CHRM2 (0.47) | CHRM2CHRM4CHRM1CHRM3MAPT | |
| SCHEMBL2008812 | 0.89 | CHRM2 (0.47) | CHRM2CHRM4CHRM1CHRM3MAPT | |
| SCHEMBL2005626 | 0.89 | CHRM2 (0.47) | CHRM2CHRM4CHRM1CHRM3MAPT | |
| SCHEMBL2005623 | 0.89 | CHRM2 (0.47) | CHRM2CHRM4CHRM1CHRM3MAPT | |
| SCHEMBL27987999 | 0.80 | CHRM2 (0.51) | CHRM2CHRM4CHRM1CHRM3CHRNA7 | |
| SCHEMBL23780837 | 0.78 | CHRM2 (0.48) | CHRM2CHRM4CHRM1CHRM3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074132-B1 | GLYCOMIMETIC REPLACEMENTS FOR HEXOSES AND N-ACETYL HEXOSAMINES | GLYCOMIMETICS INC (US) | 2013-05-15 | — | — | EP | disclosed |
| US-20120202762-A1 | METHODS OF USE OF GLYCOMIMETICS WITH REPLACEMENTS FOR HEXOSES AND N-ACETYL HEXOSAMINES | GLYCOMIMETICS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| EP-2457573-A1 | Methods of use of glycomimetics with replacements for hexoses and N-Acetyl hexosamines | GlycoMimetics, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
| US-20110257380-A1 | GLYCOMIMETIC REPLACEMENTS FOR HEXOSES AND N-ACETYL HEXOSAMINES | GLYCOMIMETICS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-8026222-B2 | Use of oligosaccharide compound or glycomimetic compound wherein a cyclohexane derivative is incorporated therein; treating inflammatory, vascular, and skin disorders such as diabetes, atherosclerosis, dermatitis, graft versus host disease, and lymphomas | GLYCOMIMETICS, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-7964569-B2 | Oligosaccharide mimetics such as {(1R,2R,3S)-2-[(6-Deoxy- alpha -L-Galactopyranosyl)Oxy]-3-Ethyl-Cyclohex-1-yl}2-O-Benzoyl-3-O-[(1S)-1-Carboxy-2-Cyclohexyl-Ethyl]- beta -D-Galactopyranoside | GLYCOMIMETICS, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20080200406-A1 | Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines | GLYCOMIMETICS, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080161546-A1 | Glycomimetic replacements for hexoses and N-acetyl hexosamines | GLYCOMIMETICS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202762-A1 | METHODS OF USE OF GLYCOMIMETICS WITH REPLACEMENTS FOR HEXOSES AND N-ACETYL HEXOSAMINES | FUT6, ENGASE, FUT5 | CHRM2 1319/4885CHRM4 997/4885CHRM1 2067/4885 |
| US-20080161546-A1 | Glycomimetic replacements for hexoses and N-acetyl hexosamines | FUT6, B3GNT2, FUT5 | CHRM2 1064/4885CHRM4 870/4885CHRM1 1769/4885 |
| US-20110257380-A1 | GLYCOMIMETIC REPLACEMENTS FOR HEXOSES AND N-ACETYL HEXOSAMINES | FUT6, B3GNT2, FUT5 | CHRM2 1064/4885CHRM4 870/4885CHRM1 1769/4885 |
| US-20080200406-A1 | Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines | FUT6, ENGASE, FUT5 | CHRM2 1319/4885CHRM4 997/4885CHRM1 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.